Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials

D Thaçi; D Jullien; A Egeberg; J M Carrascosa; J J Wu; I Pau-Charles; P Gisondi

doi:10.1111/jdv.17427

Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials

D Thaçi, D Jullien, A Egeberg, J M Carrascosa, J J Wu, I Pau-Charles, P Gisondi

Institute of Inflammation Medicine

Original language	English
Journal	Journal of the European Academy of Dermatology and Venereology : JEADV
Volume	35
Issue number	11
Pages (from-to)	e709-e711
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.17427
Publication status	Published - 11.2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/jdv.17427

Cite this

Thaçi, D., Jullien, D., Egeberg, A., Carrascosa, J. M., Wu, J. J., Pau-Charles, I., & Gisondi, P. (2021). Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. Journal of the European Academy of Dermatology and Venereology : JEADV, 35(11), e709-e711. https://doi.org/10.1111/jdv.17427

Thaçi, D ; Jullien, D ; Egeberg, A et al. / Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis : pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. In: Journal of the European Academy of Dermatology and Venereology : JEADV. 2021 ; Vol. 35, No. 11. pp. e709-e711.

@article{f595ea211b04442a81bd6d8224453e91,

title = "Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials",

author = "D Tha{\c c}i and D Jullien and A Egeberg and Carrascosa, \{J M\} and Wu, \{J J\} and I Pau-Charles and P Gisondi",

year = "2021",

month = nov,

doi = "10.1111/jdv.17427",

language = "English",

volume = "35",

pages = "e709--e711",

journal = "Journal of the European Academy of Dermatology and Venereology : JEADV",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc",

number = "11",

}

Thaçi, D, Jullien, D, Egeberg, A, Carrascosa, JM, Wu, JJ, Pau-Charles, I & Gisondi, P 2021, 'Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials', Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 35, no. 11, pp. e709-e711. https://doi.org/10.1111/jdv.17427

Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. / Thaçi, D; Jullien, D; Egeberg, A et al.
In: Journal of the European Academy of Dermatology and Venereology : JEADV, Vol. 35, No. 11, 11.2021, p. e709-e711.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis

T2 - pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials

AU - Thaçi, D

AU - Jullien, D

AU - Egeberg, A

AU - Carrascosa, J M

AU - Wu, J J

AU - Pau-Charles, I

AU - Gisondi, P

PY - 2021/11

Y1 - 2021/11

U2 - 10.1111/jdv.17427

DO - 10.1111/jdv.17427

M3 - Journal articles

C2 - 34058035

SN - 0926-9959

VL - 35

SP - e709-e711

JO - Journal of the European Academy of Dermatology and Venereology : JEADV

JF - Journal of the European Academy of Dermatology and Venereology : JEADV

IS - 11

ER -

Thaçi D, Jullien D, Egeberg A, Carrascosa JM, Wu JJ, Pau-Charles I et al. Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021 Nov;35(11):e709-e711. doi: 10.1111/jdv.17427